# Bioventus Inc.: overview BVS · Nasdaq · CIK 1665988 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bvs.md) · [Financials](/companies/bvs/financials.md) · [Filings](/companies/bvs/filings.md) · [Insiders](/companies/bvs/insiders.md) Latest reported revenue: [$153.2m](/filings/0001665988-26-000042.md) for Q2 FY2026, three months to 2026-06-27, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001665988-26-000042). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [139](/filings/0001665988-25-000026.md) | [154 d](/filings/0001665988-26-000011.md) | [124](/filings/0001665988-26-000027.md) | [148](/filings/0001665988-26-000042.md) | [139](/filings/0001665988-25-000026.md) | [158 d](/filings/0001665988-26-000011.md) | [132](/filings/0001665988-26-000027.md) | [153](/filings/0001665988-26-000042.md) | | Gross margin | % | [67.3%](/filings/0001665988-25-000026.md) | [66.8% d](/filings/0001665988-26-000011.md) | [67.0%](/filings/0001665988-26-000027.md) | [69.1%](/filings/0001665988-26-000042.md) | [68.0%](/filings/0001665988-25-000026.md) | [68.9% d](/filings/0001665988-26-000011.md) | [68.7%](/filings/0001665988-26-000027.md) | [69.0%](/filings/0001665988-26-000042.md) | | Operating margin | % | [2.6%](/filings/0001665988-25-000026.md) | [5.0% d](/filings/0001665988-26-000011.md) | [3.9%](/filings/0001665988-26-000027.md) | [12.4%](/filings/0001665988-26-000042.md) | [8.1%](/filings/0001665988-25-000026.md) | [12.3% d](/filings/0001665988-26-000011.md) | [6.4%](/filings/0001665988-26-000027.md) | [12.5%](/filings/0001665988-26-000042.md) | | Net margin | % | [(3.7%)](/filings/0001665988-25-000026.md) | [(0.3%) d](/filings/0001665988-26-000011.md) | [(2.1%)](/filings/0001665988-26-000027.md) | [5.1%](/filings/0001665988-26-000042.md) | [2.3%](/filings/0001665988-25-000026.md) | [9.3% d](/filings/0001665988-26-000011.md) | [2.4%](/filings/0001665988-26-000027.md) | [21.8%](/filings/0001665988-26-000042.md) | | Diluted EPS | $ per share | [(0.08)](/filings/0001665988-25-000026.md) | not reported | [(0.04)](/filings/0001665988-26-000027.md) | [0.11](/filings/0001665988-26-000042.md) | [0.05](/filings/0001665988-25-000026.md) | not reported | [0.04](/filings/0001665988-26-000027.md) | [0.47](/filings/0001665988-26-000042.md) | | Free cash flow | $m | [10.3 d](/filings/0001665988-25-000026.md) | [18.7 d](/filings/0001665988-26-000011.md) | [(20.2)](/filings/0001665988-26-000027.md) | [25.3 d](/filings/0001665988-26-000042.md) | [29.6 d](/filings/0001665988-25-000026.md) | [37.4 d](/filings/0001665988-26-000011.md) | [8.4](/filings/0001665988-26-000027.md) | [18.9 d](/filings/0001665988-26-000042.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [431](/filings/0001628280-24-010376.md) | [512](/filings/0001628280-25-011831.md) | [512](/filings/0001665988-26-000011.md) | [573](/filings/0001665988-26-000011.md) | [568](/filings/0001665988-26-000011.md) | | Gross margin | % | [70.3%](/filings/0001628280-24-010376.md) | [64.6%](/filings/0001628280-25-011831.md) | [64.1%](/filings/0001665988-26-000011.md) | [67.7%](/filings/0001665988-26-000011.md) | [68.3%](/filings/0001665988-26-000011.md) | | Operating margin | % | [2.8%](/filings/0001628280-24-010376.md) | [(32.7%)](/filings/0001628280-25-011831.md) | [(16.0%)](/filings/0001665988-26-000011.md) | [(2.7%)](/filings/0001665988-26-000011.md) | [9.5%](/filings/0001665988-26-000011.md) | | Net margin | % | [4.5%](/filings/0001628280-24-010376.md) | [(31.0%)](/filings/0001628280-25-011831.md) | [(30.5%)](/filings/0001665988-26-000011.md) | [(6.3%)](/filings/0001665988-26-000011.md) | [4.0%](/filings/0001665988-26-000011.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001628280-24-010376.md) | [(2.59)](/filings/0001628280-25-011831.md) | [(2.49)](/filings/0001665988-26-000011.md) | [(0.56)](/filings/0001665988-26-000011.md) | [0.33](/filings/0001665988-26-000011.md) | | Free cash flow | $m | [9.5](/filings/0001628280-24-010376.md) | [(15.0)](/filings/0001628280-25-011831.md) | [8.0](/filings/0001665988-26-000011.md) | [37.8](/filings/0001665988-26-000011.md) | [72.1](/filings/0001665988-26-000011.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bvs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Essex Woodlands Management, Inc.](/funds/1542339.md) | 2026-06-30 | $122.9m | 13,021,324 | | Unchanged | | [Juniper Investment Company, LLC](/funds/1794034.md) | 2026-06-30 | $65.5m | 6,939,357 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $56.6m | 6,000,279 | | Reduced −122,124 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $56.6m | 6,000,279 | | Reduced −122,124 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $32.4m | 3,435,914 | | Added +302,373 | | [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $17.3m | 1,833,212 | | Added +291,930 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.5m | 1,751,678 | | Added +36,971 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $12.9m | 1,365,716 | | Added +197,469 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $12.8m | 1,353,415 | | Added +733,612 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $10.7m | 1,128,465 | | Added +255,327 | ## Recent filings [All 457 filings](/companies/bvs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 07:43 ET | [10-Q](/filings/0001665988-26-000042.md) | Quarterly report, period 2026-06-27 | 0001665988-26-000042 | | 2026-08-05 | 07:40 ET | [8-K](/filings/0001665988-26-000041.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001665988-26-000041 | | 2026-06-04 | 07:54 ET | [8-K](/filings/0001665988-26-000035.md) | 5.07 Shareholder vote results | 0001665988-26-000035 | | 2026-05-21 | 16:58 ET | [8-K](/filings/0001665988-26-000029.md) | 7.01 Regulation FD disclosure | 0001665988-26-000029 | | 2026-05-06 | 07:48 ET | [10-Q](/filings/0001665988-26-000027.md) | Quarterly report, period 2026-03-28 | 0001665988-26-000027 | | 2026-05-06 | 07:46 ET | [8-K](/filings/0001665988-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001665988-26-000026 | | 2026-04-22 | 07:51 ET | [DEF 14A](/filings/0001665988-26-000014.md) | Proxy statement, period 2025-12-31 | 0001665988-26-000014 | | 2026-03-05 | 07:37 ET | [10-K](/filings/0001665988-26-000011.md) | Annual report, period 2025-12-31 | 0001665988-26-000011 | | 2026-03-05 | 07:34 ET | [8-K](/filings/0001665988-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001665988-26-000010 | | 2025-11-17 | 17:04 ET | [8-K](/filings/0001665988-25-000032.md) | 5.02 Departure or appointment of officers or directors | 0001665988-25-000032 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001665988-26-000011.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-27, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/15abb32d-3445-4fba-abbe-ececf7d0e9c2) ## About the filer - CIK: 1665988 - Tickers: BVS - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.